Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 28 02:07PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.64 Insider Own14.79% Shs Outstand66.80M Perf Week3.81%
Market Cap2.10B Forward P/E- EPS next Y-3.44 Insider Trans-3.35% Shs Float56.92M Perf Month10.77%
Income-199.42M PEG- EPS next Q-0.86 Inst Own91.93% Short Float / Ratio10.90% / 3.94 Perf Quarter89.89%
Sales0.71M P/S2951.43 EPS this Y-14.79% Inst Trans1.59% Short Interest6.20M Perf Half Y42.27%
Book/sh8.21 P/B3.82 EPS next Y4.77% ROA-38.86% Target Price46.82 Perf Year73.41%
Cash/sh8.30 P/C3.78 EPS next 5Y- ROE-44.36% 52W Range15.23 - 32.87 Perf YTD71.42%
Dividend- P/FCF- EPS past 5Y-52.45% ROI-33.46% 52W High-4.56% Beta0.56
Dividend %- Quick Ratio14.23 Sales past 5Y67.89% Gross Margin-105.50% 52W Low105.98% ATR1.59
Employees210 Current Ratio14.23 Sales Q/Q- Oper. Margin-29833.43% RSI (14)60.41 Volatility4.83% 5.83%
OptionableYes Debt/Eq0.10 EPS Q/Q-29.72% Profit Margin-28127.36% Rel Volume0.15 Prev Close31.81
ShortableYes LT Debt/Eq0.09 EarningsNov 07 AMC Payout- Avg Volume1.57M Price31.37
Recom1.09 SMA206.58% SMA509.17% SMA20045.41% Volume176,087 Change-1.38%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Overweight $35
Oct-24-23Resumed Cantor Fitzgerald Overweight $52 → $50
Aug-31-23Initiated Oppenheimer Outperform $40
Apr-24-23Initiated Piper Sandler Overweight $56
Mar-30-23Initiated Robert W. Baird Outperform $48
Nov-30-21Initiated JMP Securities Mkt Outperform $43
Nov-23-21Initiated Evercore ISI Outperform $68
Jun-18-21Upgrade JP Morgan Neutral → Overweight $28
Dec-23-19Initiated ROTH Capital Buy $37
Feb-14-19Initiated H.C. Wainwright Buy $35
Nov-20-23 04:05PM
Nov-17-23 08:39AM
Nov-10-23 05:00PM
Nov-09-23 05:45AM
Nov-08-23 09:55AM
08:50AM Loading…
Nov-07-23 04:05PM
Nov-04-23 05:03AM
Oct-23-23 09:55AM
Oct-20-23 01:02AM
Oct-11-23 09:00AM
Oct-10-23 05:00PM
Oct-03-23 07:00AM
Sep-28-23 11:18AM
08:00AM Loading…
Sep-20-23 08:00AM
Sep-15-23 08:37AM
Sep-12-23 10:26PM
Sep-11-23 04:04PM
Sep-10-23 10:00AM
Sep-05-23 08:55PM
Aug-13-23 09:02AM
Aug-10-23 05:34PM
Aug-08-23 07:00AM
Jul-31-23 08:01AM
Jul-10-23 04:18PM
07:59AM Loading…
Jun-21-23 07:59AM
Jun-12-23 07:30AM
Jun-09-23 07:30AM
May-10-23 04:21PM
May-06-23 08:07AM
May-04-23 07:35PM
Apr-16-23 09:34AM
Apr-10-23 04:31PM
Mar-28-23 03:57PM
Mar-10-23 04:37PM
Mar-06-23 07:05AM
Feb-28-23 05:25PM
Feb-10-23 05:21PM
Jan-10-23 04:48PM
Jan-09-23 08:01AM
Dec-12-22 04:01PM
Nov-28-22 08:00AM
Nov-22-22 08:00AM
Nov-14-22 09:15AM
Nov-10-22 04:30PM
Nov-06-22 07:26AM
Oct-13-22 08:00AM
Oct-10-22 04:57PM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-26-22 10:29AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 08:00AM
Aug-12-22 09:15AM
Aug-10-22 04:44PM
Aug-04-22 08:00AM
Jul-12-22 05:09PM
Jul-04-22 10:57AM
Jun-10-22 04:30PM
Jun-08-22 07:30AM
Jun-07-22 07:30AM
May-25-22 07:00AM
May-19-22 09:56AM
May-12-22 04:42PM
May-10-22 04:18PM
Apr-28-22 11:13AM
Apr-27-22 04:34PM
Apr-19-22 09:47AM
Apr-18-22 04:01PM
Apr-12-22 11:50PM
Mar-30-22 04:02PM
Mar-21-22 07:30AM
Mar-14-22 07:30AM
Mar-10-22 05:20PM
Mar-01-22 08:00AM
Feb-28-22 06:00AM
Feb-09-22 07:30AM
Feb-01-22 04:42PM
Jan-24-22 04:38AM
Jan-12-22 07:30AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-08-21 09:38AM
Nov-18-21 08:00AM
Nov-17-21 10:23AM
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Struthers Richard ScottPresident & CEONov 09Option Exercise1.9150,00095,500185,522Nov 13 04:33 PM
Struthers Richard ScottPresident & CEONov 03Option Exercise9.28199,0821,847,481334,604Nov 06 06:02 PM
Struthers Richard ScottPresident & CEONov 03Sale30.56199,0826,083,946135,522Nov 06 06:02 PM
Struthers Richard ScottPresident & CEONov 02Option Exercise9.289188,519136,440Nov 06 06:02 PM
Struthers Richard ScottPresident & CEONov 02Sale29.9591827,494135,522Nov 06 06:02 PM
Wilson MarcCFONov 01Option Exercise9.2810,00092,800105,601Nov 03 07:38 PM
Wilson MarcCFONov 01Sale28.7510,000287,50095,601Nov 03 07:38 PM
Krasner Alan SethChief Medical OfficerOct 17Option Exercise12.017,00084,07050,210Oct 19 05:01 PM
Krasner Alan SethChief Medical OfficerOct 17Sale30.007,000210,00043,210Oct 19 05:01 PM
Struthers Richard ScottPresident & CEOAug 14Option Exercise1.9110,00019,100135,522Aug 16 04:30 PM
Struthers Richard ScottPresident & CEOJul 13Sale20.3514,157288,095630,805Jul 13 04:56 PM
Struthers Richard ScottPresident & CEOJul 12Sale20.1711,459231,128644,962Jul 13 04:56 PM
Struthers Richard ScottPresident & CEOJul 11Sale20.1424,384491,094656,421Jul 13 04:56 PM
Wilson MarcCFOJun 20Option Exercise9.2820,000185,600115,158Jun 21 05:32 PM
Wilson MarcCFOJun 20Sale19.9730,922617,40395,158Jun 21 05:32 PM
Struthers Richard ScottPresident & CEOJun 16Sale20.8150,0001,040,500680,805Jun 21 05:27 PM
Vivaldi Coelho RogerioDirectorJun 08Buy22.065,000110,3005,000Jun 09 08:00 AM
Pizzuti DanaChief Development OfficerApr 05Sale16.158,212132,6244,500Apr 05 07:12 PM
Betz Stephen F.Chief Scientific OfficerFeb 01Sale19.593,12661,23864,689Feb 03 04:30 PM
Betz Stephen F.Chief Scientific OfficerJan 25Sale21.078,336175,64067,815Jan 27 04:26 PM
Betz Stephen F.Chief Scientific OfficerJan 17Sale18.003,12656,26876,151Jan 19 04:28 PM
Betz Stephen F.Chief Scientific OfficerJan 03Sale18.353,12657,36279,277Jan 05 04:23 PM
Betz Stephen F.Chief Scientific OfficerDec 15Sale16.003,12650,01682,403Dec 19 05:11 PM
Betz Stephen F.Chief Scientific OfficerDec 01Sale17.843,12655,76884,968Dec 05 05:28 PM